Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.
Int J Mol Sci
; 23(12)2022 Jun 15.
Article
in En
| MEDLINE
| ID: mdl-35743140
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Non-alcoholic Fatty Liver Disease
Type of study:
Etiology_studies
/
Prognostic_studies
Limits:
Animals
/
Humans
/
Male
Language:
En
Journal:
Int J Mol Sci
Year:
2022
Document type:
Article
Affiliation country: